•
Sep 30, 2024
Trevena Q3 2024 Earnings Report
Trevena reported a net loss for Q3 2024 and provided a business update.
Key Takeaways
Trevena reported a net loss attributable to common stockholders of $4.9 million, or $5.79 per share, compared to $7.9 million, or $14.20 per share in the third quarter of 2023. Cash and cash equivalents were $13.5 million as of September 30, 2024.
Net loss attributable to common stockholders was $4.9 million, or $5.79 per share.
Net loss was $7.9 million, or $14.20 per share in the third quarter of 2023.
Cash and cash equivalents were $13.5 million as of September 30, 2024.
Trevena is focused on developing and commercializing medicines for CNS disorders.